News for Moleculin Biotech, Inc. (MBRX)

Moleculin Biotech (MBRX) has received approval from Georgia's RAMPA for its Clinical Trial Application. This approval paves the way for the pivotal Phase 2B/3 t

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a...

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 100 points on Friday. The Dow traded down 0.09% to 42,132.74 while the ...

HOUSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., ( MBRX) (”œMoleculin” or the ”œCompany”), a late-stage pharmaceutical company with a

Summary: Moleculin Biotech (MBRX) announces the issuance of new shares and warrants, aiming to raise $5.9 million. MBRX shares experienced a significant

Moleculin Biotech (MBRX) announces a $5.9 million public offering. The offering includes 16,080,000 shares of common stock and Series E warrants for 48,

Moleculin Biotech, trading under the ticker MBRX, has announced the pricing for its public offering involving 16,080,000 shares of common stock alongside Series

On June 18, 2025, Moleculin Biotech (MBRX) received an analyst update from HC Wainwright & Co. The firm, represented by analyst Joseph Pantginis, has reiterated

Moleculin Biotech (MBRX) participated in a Virtual Investor segment to discuss FDA feedback on the Pediatric Study Plan for Annamycin. CEO Walter Klemp

Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer FDA recommends inclusion of pati

**media[658272]**

**media[658259]**

HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., ( MBRX) (”œMoleculin” or the ”œCompany”), a late-stage pharmaceutical company with

Moleculin Biotech (MBRX) will present research on Annamycin at AACR 2025. The presentation explores combining Annamycin with other drugs to boost antica

Moleculin Biotech (MBRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

**media[582762]**

Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Cash Balance: Approximately $13 million as of the end of the year, including $9 million raised in February 2025.Operating Expenses: Reduced by about $3 million

Mar 24, 2025 / 12:30PM GMTOperator Hello, and welcome to the Moleculin Biotech fourth quarter and full year 2024 update conference call and webcast. (Operator I